A
Ana M. Valero-Jimenez
Researcher at New York University
Publications - 12
Citations - 724
Ana M. Valero-Jimenez is an academic researcher from New York University. The author has contributed to research in topics: Viral replication & Microbiome. The author has an hindex of 6, co-authored 9 publications receiving 350 citations.
Papers
More filters
Journal ArticleDOI
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Kumari G. Lokugamage,Adam Hage,Maren de Vries,Ana M. Valero-Jimenez,Craig Schindewolf,Meike Dittmann,Ricardo Rajsbaum,Vineet D. Menachery +7 more
TL;DR: Evaluating type I interferon (IFN-I) sensitivity of SARS-CoV-2 relative to the original SARS -CoV indicates that while Sars-Cov-2 maintains similar viral replication to SARsCoV, the novel CoV is much more sensitive to IFn-I.
Posted ContentDOI
Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV
Kumari G. Lokugamage,Adam Hage,Maren de Vries,Ana M. Valero-Jimenez,Craig Schindewolf,Meike Dittmann,Ricardo Rajsbaum,Vineet D. Menachery +7 more
TL;DR: SARS-CoV-2 has similar replication kinetics to SARS- CoV, but demonstrates significant sensitivity to type I interferon treatment, which could help inform disease progression, treatment options, and animal model development.
Journal ArticleDOI
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19.
Maren de Vries,Adil Mohamed,Rachel A Prescott,Ana M. Valero-Jimenez,Ludovic Desvignes,Ludovic Desvignes,Rebecca E. O’Connor,Claire M. Steppan,Joseph C. Devlin,Ellie Ivanova,Alberto Herrera,Austin Schinlever,Paige Loose,Kelly V. Ruggles,Sergei B. Koralov,Annaliesa S. Anderson,Joseph John Binder,Meike Dittmann +17 more
TL;DR: In this paper, a comparative analysis of PF-00835231, the pre-clinical 3CLpro inhibitor GC-376, and the polymerase inhibitor remdesivir was performed in alveolar basal epithelial cells modified to express ACE2 (A549+ACE2 cells).
Journal ArticleDOI
The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response
Leon Louis Seifert,Clara Si,Debjani Saha,Mohammad Sadic,Maren de Vries,Sarah Ballentine,Aaron Briley,Guojun Wang,Ana M. Valero-Jimenez,Adil Mohamed,Uwe Schaefer,Hong M. Moulton,Adolfo García-Sastre,Shashank Tripathi,Shashank Tripathi,Brad R. Rosenberg,Meike Dittmann +16 more
TL;DR: Using microscopy to quantify viral infection over time, it is found that ELF1 inhibits eight diverse RNA and DNA viruses after multi-cycle replication and provides an additional layer of the innate host response, independent from the action of type I interferons.
Journal ArticleDOI
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Lucie Bernard-Raichon,Mericien Venzon,Jon Klein,Jordan E. Axelrad,Chenzheng Zhang,Alexis P. Sullivan,Grant A. Hussey,Arnau Casanovas-Massana,María G. Noval,Ana M. Valero-Jimenez,Juan Gago,Gregory G. Putzel,Alejandro Pironti,Evan Wilder,Abeer Obaid,Alice Lu-Culligan,Allison Nelson,Anderson F. Brito,Angela Hernández Núñez,Anjelica L. Martin,Anne E. Watkins,Bertie Geng,Chaney C. Kalinich,Christina A. Harden,Codruta Todeasa,Cole Jensen,Daniel J. Kim,David McDonald,D. R. Shepard,Edward M. Courchaine,Elizabeth B. White,Eric Song,Erin Silva,Eriko Kudo,Giuseppe DeIuliis,Harold Rahming,Hong Jai Park,Irene Matos,Jessica Nouws,Jordan Valdez,Joseph R. Fauver,Josephice M Lim,Kadi-Ann Rose,Kelly M. Anastasio,Kristin Brower,Laura Glick,Lokesh Sharma,Lorenzo R. Sewanan,Lynda Knaggs,Maksym Minasyan,Maria Batsu,Mary E. Petrone,Max Kuang,Maura Nakahata,Melissa Campbell,Melissa M. Linehan,Michael H. Askenase,Michael Simonov,Mikhail Smolgovsky,Nicole Sonnert,Nida Naushad,Pavithra Vijayakumar,R. Martinello,Rupak Datta,Ryan Handoko,Santos Bermejo,Sarah M Prophet,Sean Bickerton,Sofia E. Velazquez,Tara Alpert,Tyler Westcott Rice,William Khoury-Hanold,Xiaohua Peng,Yexin Yang,Yiyun Cao,Yvette E. Strong,Lorna E. Thorpe,Dan R. Littman,Meike Dittmann,Kenneth A. Stapleford,Bo Shopsin,Victor J. Torres,Albert I. Ko,Akiko Iwasaki,Ken Cadwell,Jonas Schluter +85 more
TL;DR: In this paper , the authors provide evidence that Gut microbiome dysbiosis is associated with translocation of bacteria into the blood during COVID-19, causing life-threatening secondary infections.